Synthesis and activity of three new trinuclear platinums with cis-geometry for terminal metal centres

Journal of Biomedical Science

Fazlul Huq²  Jun Q Yu²  Philip Beale¹  Shahnaz A Hamad² 

[1] Sydney Cancer Centre, Concord Hospital, Sydney NSW 2139, Australia;The University of Sydney, Cumberland Campus, Lidcombe, Sydney, NSW 2141, Australia

关键词: Pt−DNA binding;    Drug resistance;    pBR322 plasmid;    A2780;    Trinuclear;    Platinum drug;    Ovarian cancer;   

Others  :  817600
DOI  :  10.1186/1423-0127-21-41

 received in 2013-12-06, accepted in 2014-05-03,  发布年份 2014

【 摘 要 】

Background

As compared to cisplatin, trinuclear platinum compounds such as BBR3464 and DH6Cl have an altered spectrum of activity possibly because they form long-range adducts with DNA as against mainly intrastrand 1,2-bifunctional adducts formed by cisplatin and its analogues. Because of the labilizing effect associated with the trans-geometry, the compounds are expected to break down inside the cell thus serving to reduce the number of long-range adducts formed. In contrast, trinuclear platinum complexes with cis-geometry for the terminal metal centres would be less subject to such breakdown and hence may produce a greater number of long-range inter- and intrastrand adducts with the DNA. This paper describes the synthesis and activity against human ovarian tumour models of of three new trinuclear platinum complexes with cis-geometry for terminal platinum centres, coded as QH4, QH7 and QH8. The paper also describes cellular accumulation of platinum, level of drug−DNA binding, and nature of interaction of the compounds with pBR322 plasmid DNA.

Results

Methods of synthesis, elemental analysis, spectral studies and molar conductivity measurements provide support to the suggested structures of the compounds. QH4 and QH8 are found to be more cytotoxic than cisplatin against the parental A2780 cell line; QH8 is more active than cisplatin against the resistant A2780^cisR and A2780^ZD0473R cell lines as well. The least compound QH7 shows a greater activity against the resistant cell lines than the parental cell line; it is most damaging to pBR322 plasmid DNA and most able to induce changes in DNA conformation. The variations in activity of the compounds, changes in intracellular drug accumulation and levels of Pt−DNA binding with the changes in number of planaramine ligands bound to central platinum and the length of the linking diamines, can be seen (1) to illustrate structure-activity relationships and (2) to highlight that the relationship between antitumour activity and interaction with cellular platinophiles including DNA can be quite complex as the cell death is carried out by downstream processes in the cell cycle where many proteins are involved.

Conclusion

Among the three designed trinuclear platinum complexes with cis-geometry for the terminal metal centres, the most active compound QH8 is found to be more active than cisplatin against the parental A2780 and the resistant A2780^cisR and A2780^ZD0473R cell lines.

【 授权许可】

   
2014 Hamad et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Oliver T, Mead G: Testicular cancer. Curr Opin Oncol 1993, 5:559-567.
• [2]Stathopoulos GP, Rigatos S, Malamos NA: Paclitaxel combined with cisplatin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cisplatin. Oncol Rep 1999, 6:797-800.
• [3]Rosenberg B: Noble metal complexes in cancer chemotherapy. Adv Exp Med Biol 1977, 91:129-150.
• [4]Hill JM, Speer RJ: Organo-platinum complexes as antitumor agents (review). Anticancer Res 1982, 2:173-186.
• [5]Riccardi A, Meco D, Ferlini C, Servidei T, Carelli G, Segni G, Manzotti C, Riccardi R: In vitro and in vivo antitumor activity of the novel trinuclear platinum complex BBR 3464 in neuroblastoma. Cancer Chemother Pharmacol 2001, 47(6):498-504.
• [6]Huq F, Daghriri H, Yu JQ, Beale P, Fisher K: Syntheses and characterisation of four trinuclear complexes of the form: [{trans-PtCl(NH3)2}2 μ-{trans-Pd(NH3)2(H2N(CH2)nNH2)2]Cl4 where n = 4 to 7. Int J Pure and Appl Chem 2006, 1:493-507.
• [7]Huq F, Tayyem H, Yu JQ, Beale P, Fisher K: Activity of a novel trinuclear platinum complex: [{trans-PtCl(NH3)2}2 μ-{trans-Pt(3-hydroxypyridine)2(H2N(CH2)6NH2)2}]Cl4 in ovarian cancer cell lines. Chem Med Chem 2008, 10.1002:145-151. cmdc.200700204
• [8]Cheng H, Huq F, Beale P, Fisher K: Synthesis, characterisation, activities, cell uptake and DNA binding of the trinuclear complex: [{trans-PtCl(NH3)}2μ-{trans-Pd(NH3)(2-hydroxypyridine)-(H2N(CH2)6NH2)2]Cl4. Eur J Med Chem 2006, 41:896-903.
• [9]Cheng H, Huq F, Beale P, Fisher K: Synthesis, characterisation, activities, cell uptake and DNA binding of the trinuclear complex: [{trans-PtCl(NH3)}2 μ-{trans-Pt(NH3)(2-hydroxypyridine)-(H2N(CH2)6NH2)2]Cl4. Eur J Med Chem 2005, 40(8):772-781.
• [10]Chowdhury MA, Huq F, Abdullah A, Beale P, Fisher K: Synthesis, characterization and binding with DNA of four planaramineplatinum(II) complexes of the forms: trans-PtL2Cl2 and [PtL3Cl]Cl, where L = 3-hydroxypyridine, 4-hydroxypyridine and imidazo(1,2-alpha)pyridine. J Inorg Biochem 2005, 99(5):1098-1112.
• [11]Huq F, JQ Y: Molecular modeling analysis. “Why is 2- hydroxypyridine soluble in water but not 3-hydroxypyridine?”. J Mol Model 2002, 3(8):81-86.
• [12]Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65(1–2):55-63.
• [13]Di Blasi P, Bernareggi A, Beggiolin G, Piazzoni L, Menta E, Formento ML: Cytotoxicity, cellular uptake and DNA binding of the novel trinuclear platinun complex BBR 3464 in sensitive and cisplatin resistant murine leukemia cells. Anticancer Res 1998, 18(4C):3113-3117.
• [14]Bowtell DD: Rapid isolation of eukaryotic DNA. Analyt Biochem 1987, 162(2 SU):463-465.
• [15]Stellwagen N: DNA gel electrophoresis. Nucleic acid electrophoresis. New York: Springer; 1998.
• [16]Smith LA, Chirikjian JG: Purification and characterization of the sequence-specific endonuclease Bam HI. J Biol Chem 1979, 254(4):1003-1006.
• [17]Holford J, Beale PJ, Boxall FE, Sharp SY, Kelland LR: Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines. Eur J Cancer 2000, 36(15):1984-1990.
• [18]Daghriri H, Huq F, Beale P: Studies on activities, cell up take and DNA binding of four multinuclear complexes of the form: [{trans-PtCl(NH3)2}2{μ-trans-Pd(NH3)2-(H2N(CH2)nNH2)2]Cl4 where n = 4 to 7. J Inorg Biochem 2004, 98(11):1722-1733.